Fractyl
Adrian K. currently serves as the Chief Commercial Officer at Fractyl Health since April 2024, following a successful tenure at BIOTRONIK from 2019 to April 2024, where Adrian held multiple leadership roles, including Global VP & Commercial Head - Neuromodulation. Notably, Adrian developed a go-to-market strategy for spinal cord stimulation devices, achieving FDA approval and commercialization. Prior roles at BIOTRONIK included Vice President of Sales & Marketing, where Adrian led the division to a 175% growth despite the COVID-19 pandemic, and Vice President of Strategic & Corporate Accounts, focused on optimizing US commercial operations. Before BIOTRONIK, Adrian served as Area Vice President at Abbott, overseeing strategic plans in the neuromodulation sector, and held various positions at companies like OLYMPUS and Medtronic, demonstrating a consistent track record of driving commercial success in the medical device industry. Adrian holds a BSc (Hons) in Sports Science from London Metropolitan University.
This person is not in any offices
Fractyl
2 followers
Fractyl aims to bring curative therapies to the large populations of patients with metabolic disease. With their innovative products, their goal is to truly shift the treatment paradigm for patients with metabolic disease by focusing on their root cause in the intestine to provide meaningful, transformative, benefits to restore patient health from metabolic diseases.